Free tool
FAERS Monitor: Herzuma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761091 or its brand name (Herzuma, Trastuzumab-Pkrb). Reports on generic versions are filed under their own applications.
Reports
32,423
Serious
30,766
95% of reports
Hospitalization
12,261
Death reported
3,648
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea3,657
- off label use3,026
- nausea2,557
- fatigue2,208
- myelosuppression1,886
- vomiting1,727
- disease progression1,701
- neutropenia1,626
- dyspnoea1,387
- pyrexia1,340
- anaemia1,289
- neuropathy peripheral1,236
- alopecia1,216
- asthenia1,205
- ejection fraction decreased1,159
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 39 |
| 2006 | 13 |
| 2007 | 80 |
| 2008 | 152 |
| 2009 | 312 |
| 2010 | 444 |
| 2011 | 393 |
| 2012 | 699 |
| 2013 | 841 |
| 2014 | 712 |
| 2015 | 856 |
| 2016 | 810 |
| 2017 | 883 |
| 2018 | 1,720 |
| 2019 | 2,307 |
| 2020 | 2,688 |
| 2021 | 3,185 |
| 2022 | 3,200 |
| 2023 | 3,177 |
| 2024 | 4,135 |
| 2025 | 3,350 |
| 2026 | 2,402 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,736 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ejection fraction decreasedSignal | 1,159 | 52.2 | 49.2 | 53,833 |
| myelosuppressionSignal | 1,886 | 35.8 | 34.2 | 60,511 |
| disease progressionSignal | 1,701 | 9.4 | 9.0 | 12,726 |
| neuropathy peripheralSignal | 1,236 | 8.5 | 8.1 | 8,135 |
| neutropeniaSignal | 1,626 | 7.8 | 7.5 | 9,642 |
| anaemiaSignal | 1,289 | 4.4 | 4.2 | 3,400 |
| alopeciaSignal | 1,216 | 4.0 | 3.8 | 2,782 |
| diarrhoeaSignal | 3,657 | 3.7 | 3.6 | 7,355 |
| pyrexiaSignal | 1,340 | 2.5 | 2.4 | 1,241 |
| vomitingSignal | 1,727 | 2.4 | 2.3 | 1,418 |
| off label useSignal | 3,026 | 2.2 | 2.2 | 2,174 |
| nauseaSignal | 2,557 | 2.1 | 2.0 | 1,524 |
| astheniaSignal | 1,205 | 2.1 | 2.0 | 687 |
| fatigue | 2,208 | 1.8 | 1.8 | 879 |
| dyspnoea | 1,387 | 1.6 | 1.5 | 311 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.